Print Page     Close Window     

SEC Filings

20-F
AC IMMUNE SA filed this Form 20-F on 03/21/2019
Entire Document
 

CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.

 

[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.

 

Joint Development Activities Section ‎3.1.2
Joint Program IP Section ‎8.1.4
Joint Steering Committee” or “JSC Section ‎5.1
Lilly Preamble
Lilly Pre-Clinical Activities Section 3.1.2‎(ii)
Lilly Pre-Clinical Activity Period Section 3.1.2‎0(ii)
Lilly Program IP Section ‎8.1.3
Lilly Rejection Notice Section ‎3.2.3
Lilly Response Notice Section ‎3.2.3
Losses Section ‎11.1
Manufacturing Process Section ‎6.4
Non-Breaching Party Section ‎12.2.1
Notice Period Section ‎12.2.1
Opt-In Fee Section 3.2.7‎(ii)
Opt-In Premium Section 3.2.7‎(ii)
Other Product(s) Section ‎1.76
Party” and “Parties Preamble
Patent Strategy Decision Section 5.2.6‎(ii)
Patent Subcommittee Section 5.2.6‎(ii)

 

 17


© AC Immune 2015